Argonautica Private Wealth Management Inc. Has $449,000 Holdings in DexCom, Inc. (NASDAQ:DXCM)

Argonautica Private Wealth Management Inc. lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 8.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,776 shares of the medical device company’s stock after selling 540 shares during the quarter. Argonautica Private Wealth Management Inc.’s holdings in DexCom were worth $449,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of DXCM. Versant Capital Management Inc bought a new stake in DexCom during the 4th quarter valued at approximately $25,000. Heck Capital Advisors LLC acquired a new stake in shares of DexCom during the 4th quarter valued at about $38,000. Midwest Capital Advisors LLC bought a new stake in shares of DexCom in the 4th quarter valued at approximately $54,000. RPg Family Wealth Advisory LLC bought a new stake in DexCom in the third quarter valued at $57,000. Finally, Rothschild Investment LLC grew its holdings in shares of DexCom by 250.5% in the 4th quarter. Rothschild Investment LLC now owns 750 shares of the medical device company’s stock worth $58,000 after purchasing an additional 536 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on DXCM. Morgan Stanley raised their target price on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Wells Fargo & Company increased their price objective on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Finally, Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.06.

Insider Buying and Selling at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the transaction, the chief operating officer now owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,083 shares of company stock valued at $3,309,794 in the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

DexCom Trading Down 2.7 %

Shares of DexCom stock opened at $88.32 on Wednesday. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a market capitalization of $34.51 billion, a price-to-earnings ratio of 61.76, a P/E/G ratio of 2.30 and a beta of 1.14. The business has a fifty day simple moving average of $83.99 and a two-hundred day simple moving average of $76.38. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.